Your AI-Trained Oncology Knowledge Connection!
WASHINGTON-Postal patrons bought 45 million Breast Cancer stamps in the first 3.5 months after its release, raising about $3.6 million for research. Each stamp costs 8 cents more than a regular first-class stamp, with the additional money designated for funding breast cancer research at the National Institutes of Health and Department of Defense.
FLORENCE-Long-term tamoxifen (Nolvadex) treatment and polychemother-apy prevent some 20,000 to 30,000 breast cancer deaths each year and, if more widely applied, could avert as many as 50,000 such deaths, according to the latest update from the 1995-1999 data cycle of the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).
PHOENIX-Breast cancer patients age 40 and younger treated with breast conservation and irradiation have a significantly increased risk of breast recurrence and distant metastases, compared with older patients, a large retrospective French study has shown.
Sentinel lymph node biopsy, a minimally invasive procedure for staging patients with breast cancer, is a rapidly evolving technique in breast surgery. In response, a task force convened by the American Society of Breast Surgeons has issued a
As Dr. Cody points out, sentinel lymph node mapping of axillary nodes in patients with invasive breast cancer will probably become the standard of care for patients with early breast cancer, and will replace standard axillary dissection for many of these patients. With mammography increasing the detection of small, nonpalpable breast cancers, which pose a very low risk of axillary metastases, it is difficult to justify the continued use of standard axillary dissection. To my mind, it is also difficult to justify omitting axillary dissection of any type in these settings.
PHOENIX-A matched case-control study from Yale University suggests that early-stage breast cancer patients with deleterious BRCA1 or 2 mutations are at greater risk of late recurrences after breast-conserving surgery and radiation therapy than those without a mutation. Further, many of these late recurrences appear to be new primary breast cancers.
The Susan G. Komen Breast Cancer Foundation, a pioneer in the funding of research for breast cancer, announced at its 1998 National Grant Conference that the Joseph Drown Foundation has awarded the Komen Foundation a matching grant
A pharmaceutical now being considered for approval by the FDA for the diagnosis of certain lung tumors may also aid in the detection of primary and metastatic breast cancer tumors, according to a preliminary clinical study presented at the annual
FLORENCE, Italy-Although as many as 2.8% to 4.5% of all breast cancers occur during pregnancy or lactation, there are scant controlled trial data to help clinicians steer the difficult course between optimizing the outcome for the mother and protecting the child.
PHOENIX-Five-year results of a pilot study at the Ochsner Clinic, New Orleans, suggests that a 4-day course of brachytherapy may be just as effective as a 6-week course of external beam radiation therapy in breast cancer patients who have undergone breast-conserving surgery.
MIAMI BEACH-Use of aggressive induction therapy followed by high-dose chemotherapy with autologous bone marrow transplantation (ABMT) yielded a 40% complete remission rate among 425 women with metastatic breast cancer treated at Duke University Medical Center. Of these women, 11% remained in complete remission 5 years after therapy, David A. Rizzieri, MD, reported at the 40th Annual Meeting of the American Society of Hematology (ASH).
Dr. Cody presents a very thorough review of the use of sentinel lymphadenectomy in breast cancer. The article raises key issues related to a procedure that is becoming more widespread and may indeed replace axillary dissection for the staging of breast cancer.
Sentinel node surgery for breast cancer has generated considerable interest, and the timely article by Dr. Cody provides a concise, well-written review of the topic. This commentary will add a few relatively minor points and will offer some alternative viewpoints to the author’s conclusions.
Sentinel lymph node (SLN) biopsy is a rapidly emerging treatment option for patients with early-stage invasive breast cancer and a clinically negative axilla. In the era of mammographic detection, SLN biopsy has the potential to eliminate axillary dissection for the enlarging cohort of breast cancer patients who are node-negative. Using radioisotope, blue dye, or both methods, experienced surgeons can successfully localize SLNs in more than 90% of cases. The effects of isotope and blue dye may be additive. Sentinel lymph node biopsy reliably predicts axillary node status in 98% of all patients and 95% of those who are node-positive. The operation is best learned under a formalized protocol in which a backup axillary dissection is performed to validate the technique during the surgeon’s early experience. Enhanced pathologic analysis, including serial sections and immunohistochemical (IHC) staining, is an essential element of the procedure. In experienced hands, SLN biopsy has less morbidity and greater accuracy than conventional axillary dissection. [ONCOLOGY 1(13):25-34, 1999]
There are several million breast cancer survivors worldwide. In the United States, 180,000 women were diagnosed with breast cancer in 1997, and approximately 97,000 of these women have an extremely low chance of suffering a recurrence of their cancer. With an average age at diagnosis of 60 years and a 25-year expected duration of survival, the current number of breast cancer survivors in the United States may approach 2.5 million women. Since breast cancer is now being detected at an earlier stage than previously and since adjuvant chemotherapy may cause ovarian failure, an increasing number of women are becoming postmenopausal at a younger age after breast cancer treatment. This conference was convened in September 1997 to consider how menopausal breast cancer survivors should be treated at the present time and what future studies are needed to develop improved therapeutic strategies. A total of 47 breast cancer experts and 13 patient advocates participated. The proceedings of the conference will be published in six installments in successive issues of oncology. This first part defines the problem and explores its magnitude and ramifications for patient management. [ONCOLOGY 1(13):109-136, 1999]
FLORENCE, Italy-Long-term follow-up of node-negative postmenopausal breast cancer patients has shown that using tamoxifen (Nolvadex) as an adjunct to breast-conserving surgery and postoperative radiotherapy markedly improves event-free survival in these low-risk women.
In a recently issued statement, Frances M. Visco, president of the National Breast Cancer Coalition (NBCC), commended Genentech for partnering with breast cancer advocates in all aspects of the HER-2 clinical trial. “It is clear that we will only
COLUMBUS, Ohio-The Arthur G. James Cancer Hospital and Research Institute at Ohio State University was recently added to the National Comprehensive Cancer Network (NCCN) Oncology Outcomes Database, bringing the total number of medical centers participating in the database to six. The database is currently collecting data on new breast cancer patients and their treatment.
BUFFALO, NY-One use of cancer practice guidelines will be to raise the standard of care in a community and create partnerships between cancer centers and payers, Stephen Edge, MD, told the President’s Cancer Panel.
In the United States, breast cancer is the most commonly diagnosed malignancy among women and the second leading cause of cancer death. Lack of health insurance coverage often is an important financial barrier to seeking preventive health care,
DALLAS-More than 2,100 guests attended the Susan G. Komen Foundation’s 16th Annual National Awards luncheon. Candice Bergen, star of the former CBS sitcom, Murphy Brown, received the Foundation’s most prestigious honor-the Betty Ford Award-for her portrayal of the character’s battle with breast cancer during the show’s final season.
FLORENCE, Italy-Boosting both the dose intensity and dose density of adjuvant chemotherapy significantly prolongs survival in women with high-risk breast cancer, according to a multicenter trial presented at the First European Breast Cancer Conference. “A twofold dose increase in epirubicin is possible with G-CSF [Neupogen] support,” said Dr. G. Konecny of the University of Munich. “It is a feasible outpatient treatment, quality of life is good during treatment, and treatment duration is especially short.”
WASHINGTON-Times change. Twenty years ago, the word cancer was barely mentioned in the media, and the words cancer and prevention were rarely put together, Carolyn Aldige, founder of the Cancer Research Foundation of America (CRFA), said at the Foundation’s Frontline Awards ceremony. The awards went to four women whose communications activities have been instrumental in raising awareness about breast cancer.
NEW YORK-Almost half the women age 65 and over in the United States think they are not at risk for breast cancer or that they are at low risk, according to a national survey from the sponsors of National Breast Cancer Awareness Month (NBCAM).
ROCKVILLE, Md-The FDA has approved two new indications for Zeneca’s tamoxifen (Nolvadex): For reducing the incidence of breast cancer in high-risk women, and for the reduction of contralateral breast cancer. In addition, data from clinical trials that support 5 years of adjuvant Nolvadex for breast cancer patients were added to the Nolvadex label.
